Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

@article{Morse2000ConcentrationtargetedPI,
  title={Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.},
  author={Gene D. Morse and Richard C Reichman and Margaret A Fischl and Michael I. Para and John M. Leedom and William G. Powderly and Lisa M. Demeter and Lionel Resnick and Yannis Bassiakos and Joseph G. Timpone and Susan B Cox and Donald H Batts},
  journal={Antiviral research},
  year={2000},
  volume={45 1},
  pages={47-58}
}
RATIONALE To determine the dosage requirements and pharmacokinetics of atevirdine, a non-nucleoside reverse transcriptase inhibitor and its N-dealkylated metabolite (N-ATV) during phase I studies in patients receiving atevirdine alone or in combination with zidovudine. DESIGN Two open label, phase I studies conducted by the adult AIDS Clinical Trials Group (ACTG) in which atevirdine was administered every 8 h with weekly dosage adjustments to attain targeted trough plasma atevirdine… CONTINUE READING